PSA Screening and Age: New Study Maps Overdiagnosis Risk

A study published April 22 in the International Journal of Cancer reports that the rate at which PSA screening flags clinically inconsequential prostate cancers rises sharply with age. Researchers estimated that a man diagnosed through PSA screening at age 50 has roughly a 16 percent chance his cancer would never have become clinically apparent without screening; that figure rises to 32 percent at age 70 and 58 percent at age 80. The findings contribute precise, age-specific data to one of the most actively debated questions in cancer screening.

PSA, or prostate-specific antigen, is a protein produced by prostate tissue and measurable through a routine blood draw. Elevated PSA levels can indicate prostate cancer, but they can also rise in response to benign prostate enlargement, prostatitis, or other noncancerous conditions. The test has been in clinical use for decades and remains the first-line screening tool recommended by the American Urological Association. Its widespread adoption has generated sustained debate about overdiagnosis, which refers to the detection of a cancer that is histologically real but would never have progressed to cause symptoms or shorten a patient's life. Overdiagnosis is distinct from overtreatment, though the two are related: a man diagnosed with a clinically inconsequential cancer who then undergoes surgery or radiation faces real treatment risks without a meaningful net benefit. Before 2018, the U.S. Preventive Services Task Force recommended against routine PSA screening for all men; a 2018 update shifted to a shared decision-making model for men aged 55 to 69, reflecting accumulated evidence that PSA screening reduces prostate cancer mortality even as it carries overdiagnosis risk.

The research team from Queen Mary University of London analyzed long-term follow-up data from the UK CAP trial (Cluster Randomised Trial of PSA Testing for Prostate Cancer), which originally enrolled more than 400,000 men. By pairing that trial's follow-up data with English male mortality statistics, the researchers modeled the probability that a screen-detected prostate cancer would not have been identified within 15 years in the absence of any screening. Lead author Dr. Adam Brentnall noted that the United Kingdom's current practice of providing PSA tests on demand has resulted in high rates of opportunistic screening in older men, where the overdiagnosis risk is highest. For men in their 50s, the data point in the opposite direction: overdiagnosis rates at younger ages are low, meaning that cancers detected through PSA testing in this group are far more likely to be clinically meaningful. Although the analysis used UK trial data, U.S. screening guidance has moved in the same age-stratified direction. The American Urological Association and Society of Urologic Oncology updated their joint early detection guideline in February 2026 to recommend offering PSA screening every two to four years to men aged 50 to 69, continuing to emphasize shared clinical decision-making. Many urologists consider PSA trend data over time more informative than any single reading in isolation. A man who establishes a baseline PSA in his early 50s and tests periodically creates a longitudinal record that becomes far more useful when a borderline value appears years later: a rise from 1.2 ng/mL at age 51 to 2.7 ng/mL at age 56 tells a substantially different story than encountering 2.7 ng/mL for the first time. Direct-to-consumer testing allows men who do not yet have a regular urologist relationship to begin building that baseline record. LevelPanel's PSA test is available without a physician order. Background context on what the test measures and how to interpret results is available on the test page itself.

LevelPanel's PSA test can be ordered online at /tests/psa-test. After ordering, patients visit any nearby Quest Diagnostics or LabCorp patient service center for a simple blood draw without a prior physician's appointment. Results are typically available within one to three business days through a secure online portal. No fasting is required for the PSA test.

PSA screening carries the strongest evidence for men in their 50s and early 60s, and this new study reinforces that timing matters. The decision of when and how often to screen benefits from a conversation with a clinician who can weigh age, family history, and individual preferences. Establishing a baseline reading in midlife gives both patient and clinician a useful starting point for future comparisons. This article is for informational purposes and does not constitute medical advice. Consult a qualified healthcare provider regarding any health concerns.